Asston Pharmaceuticals came to market through an SME IPO that opened on 9 July 2025 and closed on 11 July 2025, and the shares listed on 16 July 2025 on SME BSE. The price band was ₹115 to ₹123 per share and one lot was 1000 shares, so the minimum application was ₹1,23,000. The issue size was ₹27.56 crore. The whole issue was fresh shares, so the money raised went to the company.
Maashitla Securities Private Limited was the registrar to the issue, and Sobhagya Capital Options Ltd was the lead manager.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Established in 2019, Asston Pharmaceuticals Limited is a pharmaceutical business dealing with the export of healthcare products worldwide. The firm deals with a wide array of products like tablets, capsules, sachets, and syrups. Its product line covers different therapeutic classes like analgesics, antibiotics, antifungals, vitamins, etc.
The company makes direct sales medicines and also on a contract manufacturing or loan license, majorly operating on a principle-to-principle basis with different marketers.The company is certified by both State and Central FDA, NQA (Nuclear Quality Assurance) accredited, and adheres to Quality Management System (QMS) guidelines in terms of high-quality production. Products: Albendazole USP 400 mg:
Albendazole USP 400 mg is a higher strength of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication which is used for the treatment of different parasitic worm infections. Diclofenac 100 mg: Diclofenac 100 mg is a particular strength of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID). Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two frequently used over-the-counter medications, typically used to relieve pain and decrease fever. Ferrovit Syrup: For the management of vitamin and mineral deficiencies.
As of 3 July 2025, there are 46 Permanent staff and 6 contractual staff in the different departments.
As described in the offer document.
| Metric | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|
Dr. Ashish Narayan Sakalkar, Saili Jayaram More, Sachin Chandrakant Badakh. Promoter holding 68.76% before the issue and 50.66% after.
Work out the listing gain for this SME IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Asston Pharmaceuticals IPO was a ₹27.56 crore book-built issue, made up entirely of a fresh issue. It was priced at ₹115–₹123 per share with a lot size of 1,000 shares; the minimum retail application was 2,000 shares (₹2,46,000). The IPO was open from July 9 to July 11, 2025. Shares listed on SME BSE on July 16, 2025 at ₹119, a 3.3% discount to the issue price of ₹123. Maashitla Securities Private Limited is the registrar.
Sobhagya Capital Options Ltd is the book running lead manager.
The price band of Asston Pharmaceuticals IPO is ₹115 to ₹123 per share.
The lot size of Asston Pharmaceuticals IPO is 1000 shares.
The minimum investment for Asston Pharmaceuticals IPO is approximately ₹1,23,000 based on the upper price band.
The allotment date of Asston Pharmaceuticals IPO is Jul 14, 2025.
Asston Pharmaceuticals IPO's final recorded GMP before listing was ₹25 per share (a 20% premium over the ₹123 upper price band). The shares listed at ₹119. GMP is unofficial and does not forecast or guarantee the actual listing price.
You can check Asston Pharmaceuticals IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Asston Pharmaceuticals IPO allotment status on Rupix for quick and easy access.
₹115 to ₹123 per share, against a face value of ₹10. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 1000 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹1,23,000. After listing, SME shares also trade in lots rather than one share at a time.
₹1,23,000, for one lot of 1000 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 9 July 2025 and closed on 11 July 2025.
The basis of allotment was published on 14 July 2025 by Maashitla Securities Private Limited, and allotted shares were credited to demat accounts before listing.
The shares listed on 16 July 2025 on SME BSE.
The issue size was ₹27.56 crore. The fresh issue was 22,41,000 shares (aggregating up to ₹27.56 crore).